文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

MNX1-AS1通过激活乳腺癌中的PI3K/AKT信号通路抑制化疗敏感性。

MNX1-AS1 suppresses chemosensitivity by activating the PI3K/AKT pathway in breast cancer.

作者信息

Shuai You, Ma Zhonghua, Yue Jian, Li Chunxiao, Ju Jie, Wang Xue, Qian Haili, Yuan Peng

机构信息

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Endoscopy, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

出版信息

Int J Biol Sci. 2025 May 27;21(8):3689-3704. doi: 10.7150/ijbs.104483. eCollection 2025.

DOI:10.7150/ijbs.104483
PMID:40520020
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12160916/
Abstract

Long noncoding RNAs (lncRNAs) critically regulate tumorigenesis and chemosensitivity. Despite the pivotal role of lncRNAs in breast cancer (BC), their specific functions and underlying mechanism, particularly in the context of drug resistance, remain largely unexplored. We discovered that MNX1-AS1 is significantly elevated in BC and contributes to paclitaxel resistance through the PI3K/AKT pathway. Moreover, elevated MNX1-AS1 expression exhibits close association with unfavourable prognosis in BC. Mechanistically, MNX1-AS1 interacts with YBX1, preventing its SMURF2-mediated ubiquitination and subsequent degradation, thereby increasing YBX1 protein levels. Upregulated YBX1 transcriptionally activates the expression of ITGA6 by binding to its promoter in the nucleus. Furthermore, MNX1-AS1 binds to IGF2BP2, promoting the stability of ITGA6 mRNA in an m6A-dependent manner within the cytoplasm. MNX1-AS1 increases ITGA6 expression at transcriptional and post-transcriptional levels, thereby activating the PI3K/AKT pathway. Notably, lipid nanoparticles were implicated to effectively deliver MNX1-AS1 siRNA to tumor-bearing mice, resulting in significant antitumor effects. These findings underscore the role of MNX1-AS1 in activating the ITGA6/PI3K/AKT pathway, which facilitates tumor progression and induces chemoresistance in BC. Targeting MNX1-AS1 may represent a promosing therapeutic strategy to enhance chemotherapy efficacy in BC patients.

摘要

长链非编码RNA（lncRNAs）对肿瘤发生和化疗敏感性起着关键的调控作用。尽管lncRNAs在乳腺癌（BC）中具有关键作用，但其具体功能和潜在机制，尤其是在耐药背景下，仍 largely未被探索。我们发现MNX1-AS1在BC中显著升高，并通过PI3K/AKT途径导致紫杉醇耐药。此外，MNX1-AS1表达升高与BC患者的不良预后密切相关。机制上，MNX1-AS1与YBX1相互作用，阻止其由SMURF2介导的泛素化及随后的降解，从而增加YBX1蛋白水平。上调的YBX1通过在细胞核中结合ITGA6的启动子转录激活其表达。此外，MNX1-AS1与IGF2BP2结合，以m6A依赖的方式在细胞质中促进ITGA6 mRNA的稳定性。MNX1-AS1在转录和转录后水平增加ITGA6表达，从而激活PI3K/AKT途径。值得注意的是，脂质纳米颗粒被证明可有效地将MNX1-AS1 siRNA递送至荷瘤小鼠体内，产生显著的抗肿瘤作用。这些发现强调了MNX1-AS1在激活ITGA6/PI3K/AKT途径中的作用，该途径促进肿瘤进展并诱导BC中的化疗耐药。靶向MNX1-AS1可能是提高BC患者化疗疗效的一种有前景的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/3471fd0699c8/ijbsv21p3689g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/0fdc32ec7d5a/ijbsv21p3689g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/444effb3826c/ijbsv21p3689g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/bbf9c328a374/ijbsv21p3689g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/adfe65f6ef00/ijbsv21p3689g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/c9d9b821e2fa/ijbsv21p3689g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/05179fa59d23/ijbsv21p3689g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/f40881cfd8f4/ijbsv21p3689g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/3471fd0699c8/ijbsv21p3689g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/0fdc32ec7d5a/ijbsv21p3689g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/444effb3826c/ijbsv21p3689g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/bbf9c328a374/ijbsv21p3689g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/adfe65f6ef00/ijbsv21p3689g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/c9d9b821e2fa/ijbsv21p3689g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/05179fa59d23/ijbsv21p3689g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/f40881cfd8f4/ijbsv21p3689g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49ce/12160916/3471fd0699c8/ijbsv21p3689g008.jpg

相似文献

[1]
MNX1-AS1 suppresses chemosensitivity by activating the PI3K/AKT pathway in breast cancer.

Int J Biol Sci. 2025-5-27

[2]
YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.

Mol Biol Rep. 2023-4

[3]
MYC-Activated LncRNA Promotes the Progression of Colorectal Cancer by Stabilizing YB1.

Cancer Res. 2021-5-15

[4]
FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.

Mol Oncol. 2021-1

[5]
Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance.

Acta Biochim Biophys Sin (Shanghai). 2021-11-10

[6]
LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.

Cancer Res. 2021-11-15

[7]
Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/ trefoil factor 1/ phosphatidylinositol 3-kinase/protein kinase B axis.

Bioengineered. 2021-12

[8]
LncRNA RUSC1-AS1 promotes osteosarcoma progression through regulating the miR-340-5p and PI3K/AKT pathway.

Aging (Albany NY). 2021-5-28

[9]
Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway.

J Cell Physiol. 2019-1-7

[10]
LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway.

Biosci Rep. 2019-1-11

本文引用的文献

[1]
M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP1.

Cancer Lett. 2024-8-28

[2]
mA modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop.

Cancer Lett. 2024-8-1

[3]
IGF2BP2 Drives Cell Cycle Progression in Triple-Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process.

Adv Sci (Weinh). 2024-1

[4]
Multiomics analyses reveal /YBX1-controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance.

Sci Adv. 2023-8-4

[5]
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy.

Adv Mater. 2023-12

[6]
HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma.

Redox Biol. 2022-12

[7]
Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer.

Nat Commun. 2022-11-22

[8]
Targeting HER2-positive breast cancer: advances and future directions.

Nat Rev Drug Discov. 2023-2

[9]
Systemic therapy for early-stage breast cancer: learning from the past to build the future.

Nat Rev Clin Oncol. 2022-12

[10]
MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc-Mediated Cell-Cycle Progression and Proliferation in Lung Cancer.

Cancer Res. 2022-12-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索